Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | cathepsin D | Starlite/ChEMBL | References |
Homo sapiens | beta-site APP-cleaving enzyme 1 | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Plasmodium falciparum | plasmepsin X | cathepsin D | 412 aa | 339 aa | 28.9 % |
Plasmodium falciparum | plasmepsin VII | beta-site APP-cleaving enzyme 1 | 401 aa | 352 aa | 21.3 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | cathepsin D (A01 family) | 0.0195 | 0.2382 | 0.2382 |
Echinococcus granulosus | muscleblind protein | 0.0145 | 0.1572 | 0.1572 |
Onchocerca volvulus | 0.0303 | 0.4118 | 1 | |
Echinococcus multilocularis | microtubule associated protein 2 | 0.0668 | 1 | 1 |
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.005 | 0.0053 | 0.0129 |
Echinococcus multilocularis | cathepsin d (lysosomal aspartyl protease) | 0.008 | 0.0531 | 0.0531 |
Schistosoma mansoni | microtubule-associated protein tau | 0.0668 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0145 | 0.1572 | 0.3818 |
Loa Loa (eye worm) | hypothetical protein | 0.0303 | 0.4118 | 1 |
Schistosoma mansoni | subfamily S1A unassigned peptidase (S01 family) | 0.0303 | 0.4118 | 0.4118 |
Plasmodium falciparum | plasmepsin VI | 0.008 | 0.0531 | 1 |
Plasmodium falciparum | plasmepsin IV | 0.008 | 0.0531 | 1 |
Echinococcus granulosus | cathepsin d lysosomal aspartyl protease | 0.008 | 0.0531 | 0.0531 |
Echinococcus multilocularis | muscleblind protein 1 | 0.0145 | 0.1572 | 0.1572 |
Schistosoma mansoni | memapsin-2 (A01 family) | 0.0535 | 0.7856 | 0.7856 |
Loa Loa (eye worm) | aspartic protease BmAsp-2 | 0.008 | 0.0531 | 0.1289 |
Onchocerca volvulus | 0.0264 | 0.3496 | 0.8488 | |
Trichomonas vaginalis | Clan AA, family A1, cathepsin D-like aspartic peptidase | 0.008 | 0.0531 | 0.5 |
Plasmodium falciparum | plasmepsin I | 0.008 | 0.0531 | 1 |
Toxoplasma gondii | PAN domain-containing protein | 0.059 | 0.8736 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0145 | 0.1572 | 0.3818 |
Toxoplasma gondii | aspartyl protease ASP1 | 0.008 | 0.0531 | 0.0608 |
Plasmodium vivax | aspartyl proteinase, putative | 0.008 | 0.0531 | 1 |
Schistosoma mansoni | cathepsin D (A01 family) | 0.0195 | 0.2382 | 0.2382 |
Plasmodium vivax | plasmepsin IV, putative | 0.008 | 0.0531 | 1 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.005 | 0.0053 | 0.0129 |
Schistosoma mansoni | subfamily A1A unassigned peptidase (A01 family) | 0.008 | 0.0531 | 0.0531 |
Loa Loa (eye worm) | hypothetical protein | 0.008 | 0.0531 | 0.1289 |
Trypanosoma cruzi | hypothetical protein, conserved | 0.0047 | 0 | 0.5 |
Toxoplasma gondii | aspartyl proteinase (eimepsin), putative | 0.008 | 0.0531 | 0.0608 |
Loa Loa (eye worm) | hypothetical protein | 0.005 | 0.0053 | 0.0129 |
Brugia malayi | Muscleblind-like protein | 0.0145 | 0.1572 | 0.3818 |
Plasmodium falciparum | plasmepsin II | 0.008 | 0.0531 | 1 |
Echinococcus multilocularis | muscleblind protein | 0.0145 | 0.1572 | 0.1572 |
Schistosoma mansoni | subfamily S1A unassigned peptidase (S01 family) | 0.0303 | 0.4118 | 0.4118 |
Brugia malayi | Corticotropin releasing factor receptor 2 precursor, putative | 0.005 | 0.0053 | 0.0129 |
Toxoplasma gondii | PAN domain-containing protein | 0.059 | 0.8736 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0303 | 0.4118 | 1 |
Brugia malayi | Trypsin family protein | 0.0303 | 0.4118 | 1 |
Leishmania major | hypothetical protein, conserved | 0.0047 | 0 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
ED50 (binding) | = 84 nM | Inhibition of BACE1 in HEK293 cells expressing swedish mutant APP FAD isoform | ChEMBL. | 20833041 |
IC50 (binding) | = 1300 nM | Inhibition of recombinant BACE1 purified from Escherichia coli | ChEMBL. | 20833041 |
IC50 (binding) | > 10000 nM | Inhibition of cathepsin-D | ChEMBL. | 20833041 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.